Federal Register: FDA · October 16, 2026 · Primary source
Electronic Common Technical Document; Data Standards; Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research Supporting Electronic Common Technical Document Version 3.2.2 and Version 4.0
Summary
FDA published a Federal Register notice announcing the dates on which it will begin rejecting electronic drug and biologics submissions that fail new high-severity validation rules under eCTD Version 3.2.2 and Version 4.0. The new v3.2.2 validations are numbered 2024 and 2025, and the new v4.0 validations include eCTD4-084, eCTD4-085, and four US-specific criteria. Submissions that do not satisfy these validation criteria will be rejected outright by FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research.
What this may mean
Pharmaceutical and biologics manufacturers and their regulatory affairs teams face outright rejection of electronic submissions that do not conform to the newly enforced eCTD validation rules. The change affects the technical format of regulatory filings, not billing, prescribing, or compliance program obligations for healthcare providers or payors.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- Federal Register: FDA · October 21, 2026Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; AvailabilityScore 51
- Federal Register: FDA · October 16, 2026Electronic Common Technical Document (eCTD); Data Standards; Supporting Forward Compatibility for eCTD 4.0Score 30
- Federal Register: FDA · October 7, 2026Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; CorrectionScore 30
- Federal Register: FDA · October 15, 2026Authorization of Emergency Use for Four Animal Drugs for the Prevention and Treatment of New World Screwworm; AvailabilityScore 28
- Federal Register: FDA · October 9, 2026Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Expanded Access to Investigational Drugs for Treatment UseScore 28
- Federal Register: FDA · October 16, 2026Fit-for-Purpose Rare Disease Framework Initiative; Public Meeting; Request for Information and CommentsScore 26